<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04987658</url>
  </required_header>
  <id_info>
    <org_study_id>ALKS 3831-A311</org_study_id>
    <nct_id>NCT04987658</nct_id>
  </id_info>
  <brief_title>Phase 1 Study of OLZ/SAM in Pediatric Subjects With Bipolar I Disorder</brief_title>
  <official_title>A Phase 1, Multiple-dose, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of OLZ/SAM in Pediatric Subjects (10-12 Years Old) With Bipolar I Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alkermes, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alkermes, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety, tolerability, and pharmacokinetics of olanzapine and samidorphan in&#xD;
      clinically stable pediatric subjects (10 to 12 years old) with Bipolar I disorder following&#xD;
      oral administration of multiple ascending doses of OLZ/SAM&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 22, 2021</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum plasma concentration observed</measure>
    <time_frame>Up to 3 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve over the 24-hour dosing interval</measure>
    <time_frame>Up to 3 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach maximum concentration</measure>
    <time_frame>Up to 3 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>Up to 6 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Bipolar I Disorder</condition>
  <arm_group>
    <arm_group_label>Group 1 Olanzapine/ 5 mg Samidorphan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Olanzapine will be gradually increased to a target dose of 10mg/samidorphan 5mg (Range: 5-20mg Olanzapine/samidorphan 5mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 Olanzapine/ 10mg Samidorphan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Olanzapine will be gradually increased to a target dose of 10mg/samidorphan 10mg (Range: 5-20mg Olanzapine/samidorphan 10mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OLZ/SAM</intervention_name>
    <description>Olanzapine and Samidorphan taken once daily over a max period of 21 days</description>
    <arm_group_label>Group 1 Olanzapine/ 5 mg Samidorphan</arm_group_label>
    <arm_group_label>Group 2 Olanzapine/ 10mg Samidorphan</arm_group_label>
    <other_name>ALKS 3831</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject's parent(s)/legal guardian(s) is considered reliable by the Investigator and&#xD;
             has agreed to provide support to the subject to ensure compliance with study&#xD;
             treatment, visits, and protocol procedures.&#xD;
&#xD;
          -  Male and female subjects between 10 and 12 years of age, inclusive.&#xD;
&#xD;
          -  Subject weighs ≥70 pounds.&#xD;
&#xD;
          -  Subjects who are receiving antipsychotic treatment for their medical condition, with a&#xD;
             diagnosis of bipolar I disorder.&#xD;
&#xD;
          -  Subjects must be considered stable, per investigator judgement.&#xD;
&#xD;
          -  Subject is willing to abide by the contraception requirements for the duration of the&#xD;
             study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has a comorbid neuropsychiatric disorder that could interfere with&#xD;
             participation in the study.&#xD;
&#xD;
          -  Subject poses a current suicide risk as assessed by the Investigator or as confirmed&#xD;
             by the baseline Columbia-Suicide Severity Rating Scale by a response of &quot;Yes&quot; to&#xD;
             question numbers 4 or 5 with ideation or suicidal behavior occurring in the past 12&#xD;
             months (assessed at Screening and at Visit 2, Day 1).&#xD;
&#xD;
          -  Subject has a diagnosis of diabetes or presents with pre-diabetes lab results&#xD;
             (hemoglobin A1c ≥6%).&#xD;
&#xD;
          -  Subject has a history of use of clozapine or use of long-acting injectable&#xD;
             antipsychotic medication within 3 months prior to Screening.&#xD;
&#xD;
          -  Subject has a DSM-5 (Diagnostic and Statistical Manual of Mental Disorders-5)&#xD;
             diagnosis of moderate to severe alcohol disorder, or moderate to severe substance use&#xD;
             disorder, within the 3 months prior to Screening.&#xD;
&#xD;
          -  Subject has taken opioid agonists within the 14 days prior to Screening, or has taken&#xD;
             long-acting opioid agonist within the 30 days prior to Screening, or has anticipated a&#xD;
             need to take opioid medication during the study period (eg, planned surgery, including&#xD;
             oral surgery), or has taken opioid antagonists including naltrexone (any formulation)&#xD;
             and naloxone within 60 days prior to Screening.&#xD;
&#xD;
          -  Subject is unable to swallow oral medications, as assessed by the Investigator.&#xD;
&#xD;
          -  Subject has a positive urine drug screen for opioids (assessed at Screening and at&#xD;
             Visit 2, Day 1).&#xD;
&#xD;
          -  Subject has a positive cotinine test (assessed at Screening and at Visit 2, Day 1).&#xD;
&#xD;
          -  Subject has an intellectual disability, as assessed by the Investigator.&#xD;
&#xD;
          -  Subject has a history of intolerance or hypersensitivity to olanzapine or opioid&#xD;
             antagonists, or any component of the study drug.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David McDonnell, MD</last_name>
    <role>Study Director</role>
    <affiliation>Alkermes, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Senrior Director, Global Clinical Services</last_name>
    <phone>888-235-8008 (US Only)</phone>
    <email>clinicaltrials@alkermes.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Senrior Director, Global Clinical Services</last_name>
    <phone>571-599-2702 (Global)</phone>
    <email>clinicaltrials@alkermes.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Alkermes Clinical Investigative Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alkermes Clinical Investigative Site</name>
      <address>
        <city>Everett</city>
        <state>Washington</state>
        <zip>98201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 26, 2021</study_first_submitted>
  <study_first_submitted_qc>August 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2021</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bipolar I Disorder</keyword>
  <keyword>Olanzapine</keyword>
  <keyword>Samidorphan</keyword>
  <keyword>OLZ/SAM</keyword>
  <keyword>ALKS 3831</keyword>
  <keyword>Pediatric pharmacokentics</keyword>
  <keyword>LYBALVI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

